World leader in contract research, development and manufacturing, Solvias, has announced an agreement completion with strategic health care investors, Water Street Healthcare Partners and JLL Partners, to wholly acquire and invest in the growing company.

The agreement is the next step in Solvias’ expansion focused on building the company into a global leader of high-quality pharmaceutical laboratory services.

Solvias will engage Water Street and JLL’s industry expertise and network of resources to extend the company’s capabilities into new and complementary areas and expand its global reach. Solvias also announced today that the health care firms helped recruit two seasoned pharmaceutical services executives to join its board of directors. Solvias has appointed Michael J. Lehmann and Mario L. Rocci, Jr., PhD to join Karen J. Huebscher, PhD, chief executive officer and director of Solvias, on the company’s board:

  • Michael J Lehmann, chairman, is the former chief commercial officer and president of global pharmaceutical development services for Patheon N.V., where he was instrumental in Patheon’s transformation to high-growth contract development and manufacturing organisation. Mr Lehmann also spearheaded global early development for Covance Inc. Most recently, he served on the board of BioAgilytix Labs.
  • Mario L Rocci Jr, director, has more than 30 years of leadership experience in the pharmaceutical services industry and is the former president of ICON plc’s early phase clinical, laboratory, and scientific services division. Dr Rocci also served as chairman of the Product Quality Research Institute and president of the American Association of Pharmaceutical Scientists.

“We’re thrilled to be growing Solvias in partnership with our new investors and board,” said Dr Huebscher. “Since Solvias’ founding, we have continuously innovated and expanded our platform of testing, specialised pharmaceutical manufacturing products, analytical kits and services to offer our customers the highest level of scientific expertise and technical capabilities. These newest initiatives support our goal of bringing greater value to our customers and positioning Solvias at the forefront of our industry.”

Founded in 1999, Solvias has grown to serve more than 600 biotech, medical device, cosmetic and top multinational pharmaceutical companies. In recent years, the company has extended its testing and analytical services to address biopharmaceutical products and emerging cell and gene therapies. Solvias has remained fully operational during the current pandemic crisis, providing critical services to customers, including supporting their work to develop therapeutic options and vaccine candidates for Covid-19.

“Solvias is highly regarded for its outstanding quality of work, scientific expertise and commitment to continuous innovation. Its work is critical to supporting organisations with bringing important, life-saving products to market. I’m honoured to work with Karen and her team to support their goal of building Solvias into a global industry leader,” said Mr Lehmann.

For more information, please fill out the enquiry form attached to this page.